

## DAFTAR PUSTAKA

1. Pham, C. D. *et al.* Aaptamine derivatives from the Indonesian sponge *Aaptos suberitoides*. *J Nat Prod* **76**, 103–106 (2013).
2. Fu, W. *et al.* Bioactive Compounds From Microalgae: Current Development and Prospects. in *Studies in Natural Products Chemistry* vol. 54 199–225 (Elsevier B.V., 2017).
3. Kiuru, P. *et al.* Exploring Marine Resources for Bioactive Compounds. *Planta Med* 1–13 (2014) doi:<http://dx.doi.org/10.1055/s-0034-1383001>.
4. Hardani, I. N., Damara, F. A., Nugrahani, A. D. & Bashari, M. H. Ethanol Extract of *Stylissa carteri* Induces Cell Death in Parental and Paclitaxel-Resistant Cervical Cancer Cells. *International Journal of Integrated Health Sciences* **6**, 91–96 (2018).
5. Daffa, D. M., Bashari, M. H., Ariyanto, E. F., Putri, T. & Qomarilla, N. Anti-migration Effect of *Aaptos suberitoides* Fraction in HCT-116 Colorectal Cancer Cell Line. *Althea Medical Journal* **8**, (2021).
6. Bashari, M. H. *et al.* Bioactive compounds in the ethanol extract of marine sponge *Stylissa carteri* demonstrates potential anti-cancer activity in breast cancer cells. *Asian Pacific Journal of Cancer Prevention* **20**, 1199–1206 (2019).
7. Farooq, S. *et al.* Discovery of a Secalonic Acid Derivative from *Aspergillus aculeatus*, an Endophyte of *Rosa damascena* Mill., Triggers Apoptosis in MDA-MB-231 Triple Negative Breast Cancer Cells. *ACS Omega* **5**, 24296–24310 (2020).
8. Esposito, R. *et al.* Sponges and their symbionts as a source of valuable compounds in the cosmeceutical field. *Marine Drugs* vol. 19 Preprint at <https://doi.org/10.3390/md19080444> (2021).
9. Masoud, V. & Pagès, G. Targeted therapies in breast cancer: New challenges to fight against resistance. *World Journal of Clinical Oncology* vol. 8 120–134 Preprint at <https://doi.org/10.5306/wjco.v8.i2.120> (2017).
10. Huang, M., Shen, A., Ding, J. & Geng, M. Molecularly targeted cancer therapy: Some lessons from the past decade. *Trends in Pharmacological Sciences* vol. 35 41–50 Preprint at <https://doi.org/10.1016/j.tips.2013.11.004> (2014).
11. Zhang, S. *et al.* Comparative metabolomic analysis reveals shared and unique chemical interactions in sponge holobionts. *Microbiome* **10**, (2022).
12. Ferreira, L. G., Dos Santos, R. N., Oliva, G. & Andricopulo, A. D. Molecular docking and structure-based drug design strategies. *Molecules* vol. 20 13384–13421 Preprint at <https://doi.org/10.3390/molecules200713384> (2015).
13. Shibata, T. *et al.* Genetic Alteration of Keap1 Confers Constitutive Nrf2 Activation and Resistance to Chemotherapy in Gallbladder Cancer. *Gastroenterology* **135**, (2008).
14. Wang, X. J. *et al.* Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. *Carcinogenesis* **29**, 1235–1243 (2008).
15. Denicola, G. M. *et al.* Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. *Nature* **475**, 106–110 (2011).
16. Hayes, J. D. & McMahon, M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. *Trends in Biochemical Sciences* vol. 34 176–188 Preprint at <https://doi.org/10.1016/j.tibs.2008.12.008> (2009).
17. Van Anh, C. *et al.* Polyketides and meroterpenes from the marine-derived fungi *Aspergillus unguis* 158SC-067 and *A. flocculosus* 01NT-1.1.5 and their cytotoxic and antioxidant activities. *Mar Drugs* **19**, (2021).
18. Trianto, A., Ridhlo, A., Triningsih, D. W. & Tanaka, J. Study on Anticancer Activity of Extracts of Sponges Collected from Biak Water, Indonesia. in *IOP Conference*

Series: *Earth and Environmental Science* vol. 55 (Institute of Physics Publishing, 2017).

19. Pham, C. D. *et al.* Aaptamine derivatives from the Indonesian sponge *Aaptosuberitoides*. *J Nat Prod* **76**, 103–106 (2013).
20. Pham, C. D. *et al.* Aaptamine derivatives from the Indonesian sponge *Aaptosuberitoides*. *J Nat Prod* **76**, 103–106 (2013).
21. Sajna, K. V., Kamat, S. & Jayabaskaran, C. Antiproliferative Role of Secondary Metabolites From *Aspergillus unguis* AG 1.1 (G) Isolated From Marine Macroalgae *Enteromorpha* sp. by Inducing Intracellular ROS Production and Mitochondrial Membrane Potential Loss Leading to Apoptosis. *Front Mar Sci* **7**, (2020).
22. Parwata, I. M. O. A. *Bahan Ajar Antioksidan. Kimia Terapan Program Pascasarjana Universitas Udayana* (2016).
23. Sayuti, K. & Yenrina, R. *Natural and Synthetic Antioxidants*. Andalas University Press (Andalas University Press, 2015).
24. Nimse, S. B. & Pal, D. Free radicals, natural antioxidants, and their reaction mechanisms. *RSC Adv* **5**, (2015).
25. Proctor, P. H. & Reynolds, E. S. Free radicals and disease in man. *Physiological chemistry and physics and medical NMR* vol. 16 Preprint at (1984).
26. Valko, M., Izakovic, M., Mazur, M., Rhodes, C. J. & Telser, J. Role of oxygen radicals in DNA damage and cancer incidence. *Mol Cell Biochem* **266**, (2004).
27. Kesarwala, A., Krishna, M. & Mitchell, J. Oxidative stress in oral diseases. *Oral Dis* **22**, 9–18 (2016).
28. Kim, S. J., Kim, H. S. & Seo, Y. R. Understanding of ROS-Inducing Strategy in Anticancer Therapy. *Oxidative Medicine and Cellular Longevity* vol. 2019 Preprint at <https://doi.org/10.1155/2019/5381692> (2019).
29. Pisoschi, A. M. & Pop, A. The role of antioxidants in the chemistry of oxidative stress: A review. *European Journal of Medicinal Chemistry* vol. 97 55–74 Preprint at <https://doi.org/10.1016/j.ejmech.2015.04.040> (2015).
30. Sies, H. Oxidative stress: A concept in redox biology and medicine. *Redox Biology* vol. 4 180–183 Preprint at <https://doi.org/10.1016/j.redox.2015.01.002> (2015).
31. Baird, L. & Yamamoto, M. The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway. *Mol Cell Biol* **40**, (2020).
32. Taguchi, K., Motohashi, H. & Yamamoto, M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. *Genes to Cells* vol. 16 123–140 Preprint at <https://doi.org/10.1111/j.1365-2443.2010.01473.x> (2011).
33. Hayes, J. D. & McMahon, M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. *Trends in Biochemical Sciences* vol. 34 176–188 Preprint at <https://doi.org/10.1016/j.tibs.2008.12.008> (2009).
34. Kansanen, E., Kuosmanen, S. M., Leinonen, H. & Levonenn, A. L. The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. *Redox Biology* vol. 1 45–49 Preprint at <https://doi.org/10.1016/j.redox.2012.10.001> (2013).
35. Eades, G., Yang, M., Yao, Y., Zhang, Y. & Zhou, Q. miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells. *Journal of Biological Chemistry* **286**, 40725–40733 (2011).
36. Ghareghomi, S., Habibi-Rezaei, M., Arese, M., Saso, L. & Moosavi-Movahedi, A. A. Nrf2 Modulation in Breast Cancer. *Biomedicines* vol. 10 Preprint at <https://doi.org/10.3390/biomedicines10102668> (2022).
37. Denicola, G. M. *et al.* Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. *Nature* **475**, 106–110 (2011).

38. Wang, X. J. *et al.* Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. *Carcinogenesis* **29**, 1235–1243 (2008).
39. Deshmukh, P., Unni, S., Krishnappa, G. & Padmanabhan, B. The Keap1–Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. *Biophysical Reviews* vol. 9 41–56 Preprint at <https://doi.org/10.1007/s12551-016-0244-4> (2017).
40. Bellezza, I., Giambanco, I., Minelli, A. & Donato, R. Nrf2-Keap1 signaling in oxidative and reductive stress. *Biochimica et Biophysica Acta - Molecular Cell Research* vol. 1865 721–733 Preprint at <https://doi.org/10.1016/j.bbamcr.2018.02.010> (2018).
41. Araujo, J. A., Zhang, M. & Yin, F. Heme oxygenase-1, oxidation, inflammation, and atherosclerosis. *Frontiers in Pharmacology* vol. 3 JUL Preprint at <https://doi.org/10.3389/fphar.2012.00119> (2012).
42. Wu, C. T. *et al.* Salvianolic Acid C against acetaminophen-induced acute liver injury by attenuating inflammation, oxidative stress, and apoptosis through inhibition of the Keap1/Nrf2/HO-1 signaling. *Oxid Med Cell Longev* **2019**, (2019).
43. Wu, C. T. *et al.* Salvianolic Acid C against acetaminophen-induced acute liver injury by attenuating inflammation, oxidative stress, and apoptosis through inhibition of the Keap1/Nrf2/HO-1 signaling. *Oxid Med Cell Longev* **2019**, (2019).
44. Alonso, A., Marsal, S. & Julià, A. Analytical methods in untargeted metabolomics: State of the art in 2015. *Frontiers in Bioengineering and Biotechnology* vol. 3 Preprint at <https://doi.org/10.3389/fbioe.2015.00023> (2015).
45. Harmita, K., Harahap, Y. & Supandi. *Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)*. vol. 1 (PT. ISFI Penerbitan, 2019).
46. Lipinski, C. A. Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. *Advanced Drug Delivery Reviews* vol. 101 34–41 Preprint at <https://doi.org/10.1016/j.addr.2016.04.029> (2016).
47. Yadav, P., Kumar, A., Mahour, K. & Vihan, V. S. Phytochemical Analysis of Some Indigenous Plants Potent Against Endoparasite. *Journal of Advanced Laboratory Research in Biology* **1**, 1–4 (2020).
48. Egbuna, C., Ifemeje, J. C., Udedi, S. C. & Kumar, S. *PhytoChemistry*. (CHUKWUEBUKA EGBUNA, 2020). doi:DOI: 10.13140/RG.2.2.18812.2368.
49. Zhou, W. C., Zhang, Q. B. & Qiao, L. Pathogenesis of liver cirrhosis. *World J Gastroenterol* **20**, (2014).
50. Neffati, A. *et al.* A comparative evaluation of mutagenic, antimutagenic, radical scavenging and antibacterial activities of essential oils of *Pituranthos chloranthus*. *Drug Chem Toxicol* **32**, (2009).
51. Brand-Williams, W., Cuvelier, M. E. & Berset, C. Use of a free radical method to evaluate antioxidant activity. *LWT - Food Science and Technology* vol. 28 Preprint at [https://doi.org/10.1016/S0023-6438\(95\)80008-5](https://doi.org/10.1016/S0023-6438(95)80008-5) (1995).
52. Fu, R., Zhang, Y., Guo, Y., Liu, F. & Chen, F. Determination of phenolic contents and antioxidant activities of extracts of *Jatropha curcas* L. seed shell, a by-product, a new source of natural antioxidant. *Ind Crops Prod* **58**, (2014).
53. Antolovich, M., Prenzler, P. D., Patsalides, E., McDonald, S. & Robards, K. Methods for testing antioxidant activity. *Analyst* vol. 127 Preprint at <https://doi.org/10.1039/b009171p> (2002).
54. Echegaray, N. *et al.* Measurement of antioxidant capacity of meat and meat products: Methods and applications. *Molecules* vol. 26 Preprint at <https://doi.org/10.3390/molecules26133880> (2021).

55. Meng, X.-Y., Zhang, H.-X., Mezei, M. & Cui, M. Molecular Docking: A powerful approach for structure-based drug discovery. *National Institutes of Health* **7** (2), 1–24 (2011).
56. Khelifaoui, H., Harkati, D. & Saleh, B. A. Molecular docking, molecular dynamics simulations and reactivity, studies on approved drugs library targeting ACE2 and SARS-CoV-2 binding with ACE2. *J Biomol Struct Dyn* **39**, 7246–7262 (2021).
57. Moulishankar, A. & Lakshmanan, K. Data on molecular docking of naturally occurring flavonoids with biologically important targets. *Data Brief* **29**, 105243 (2020).
58. Morris, G. M. & Lim-Wilby, M. Molecular Docking. in *Molecular Modeling of Proteins* (ed. Kukol, A.) 365–382 (Humana Press, 2008). doi:10.1007/978-1-59745-177-2\_19.
59. Leach, A. R. *Molecular Modelling PRINCIPLES AND APPLICATIONS*. vol. 1 (Longman imprint, 2001).
60. Morris, G. M. *et al.* AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J Comput Chem* **30**, 2785–2791 (2009).
61. Jain, A. N. *Scoring Functions for Protein-Ligand Docking*. *Current Protein and Peptide Science* vol. 7 (2006).
62. John, M., Pintacuda, G., Park, A. Y., Dixon, N. E. & Otting, G. Structure Determination of Protein–Ligand Complexes by Transferred Paramagnetic Shifts. *J Am Chem Soc* **128**, 12910–12916 (2006).
63. Kitchen, D. B., Decornez, H., Furr, J. R. & Bajorath, J. Docking and scoring in virtual screening for drug discovery: methods and applications. *Nat Rev Drug Discov* **3**, 935–949 (2004).
64. Vilar, S., Cozza, G. & Moro, S. Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. *Curr Top Med Chem* **8**, 1555–1572 (2008).
65. Halgren, T. A. Identifying and characterizing binding sites and assessing druggability. *J Chem Inf Model* **49**, 377–389 (2009).
66. Pelletier, S. W. *Alkaloids: Chemical and Biological Perspectives*. *Alkaloids: Chemical and Biological Perspectives* vol. 7 (Springer New York, 1991).
67. Surowiak, A. K., Balcerzak, L., Lochyński, S. & Strub, D. J. Biological activity of selected natural and synthetic terpenoid lactones. *International Journal of Molecular Sciences* vol. 22 Preprint at <https://doi.org/10.3390/ijms22095036> (2021).
68. Teponno, R. B., Kusari, S. & Spiteller, M. Recent advances in research on lignans and neolignans. *Natural Product Reports* vol. 33 1044–1092 Preprint at <https://doi.org/10.1039/c6np00021e> (2016).
69. Aggarwal, B. B., Sundaram, C., Malani, N. & Ichikawa, H. *CURCUMIN: THE INDIAN SOLID GOLD*. (2007).
70. Jeong, Y. *et al.* A pilot study evaluating steroid-induced diabetes after antiemetic dexamethasone therapy in chemotherapy-treated cancer patients. *Cancer Res Treat* **48**, 1429–1437 (2016).
71. Yao, L. H. *et al.* *Flavonoids in Food and Their Health Benefits*. *Plant Foods for Human Nutrition* vol. 59 (2004).
72. Lipinski, C. A. Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. *Adv Drug Deliv Rev* **101**, 34–41 (2016).
73. Domingos, L. T. S. *et al.* Secondary Metabolites Diversity of *Aspergillus unguis* and Their Bioactivities: A Potential Target to Be Explored. *Biomolecules* vol. 12 Preprint at <https://doi.org/10.3390/biom12121820> (2022).

74. Molyneux, P. The Use of the Stable Free Radical Diphenylpicryl-hydrazyl (DPPH) for Estimating Antioxidant Activity. *Songklanakarin Journal of Science and Technology* **26**, (2004).
75. Neti, L., Larasati, V. & Permahanani, A. Natural Combination Extract of Mangosteen Pericarp and Phycocyanin of *Spirulina Platensis* Decreases Plasma Malonaldehyde Level In Acute Exercise-Induced Oxidative Stress. *Majalah Ilmiah Sriwijaya* **XXX**, (2018).
76. Sajna, K. V., Kamat, S. & Jayabaskaran, C. Antiproliferative Role of Secondary Metabolites From *Aspergillus unguis* AG 1.1 (G) Isolated From Marine Macroalgae *Enteromorpha* sp. by Inducing Intracellular ROS Production and Mitochondrial Membrane Potential Loss Leading to Apoptosis. *Front Mar Sci* **7**, (2020).
77. Fristiody, A. *et al.* Isolation and identification of secondary metabolite acetone extract *Aptos* sp. and its antioxidant properties and acute toxicity. *J Appl Pharm Sci* **10**, 81–89 (2020).
78. Putri, D. A., Radjasa, O. K. & Pringgenies, D. Effectiveness of Marine Fungal Symbiont Isolated from Soft Coral *Sinularia* sp. from Panjang Island as Antifungal. *Procedia Environ Sci* **23**, 351–357 (2015).
79. Abd, F. K., Hady, E., Shaker, K. & Elshahid, Z. A. *Antioxidant, Acetylcholinesterase and  $\alpha$ -glucosidase potentials of metabolites from the marine fungus *Aspergillus unguis* RSPG\_204 associated with the sponge (*Agelas* sp.) GC-MS Analysis of Ethanol Extract of *Solanum* Species and Populations from Saudi Arabia and their Systematics Implications View project. Article in International Journal of Pharmaceutical Sciences Review and Research* vol. 30 [www.globalresearchonline.net](http://www.globalresearchonline.net) (2015).
80. Rivera, A. P. & Uy, M. M. In Vitro Antioxidant and Cytotoxic Activities of Some Marine Sponges Collected off Misamis Oriental Coast, Philippines. *E-Journal of Chemistry* **9**, 354–358 (2011).
81. Nelson, D. L. & Cox, M. M. *Lehninger PRINCIPLES of BIOCHEMISTRY*. vol. 7 (W. H. Freeman, 2017).
82. Berg, J. M., Tymoczko, J. L., Gatto Jr, G. J. & Stryer, Lubert. *Biochemistry*. (2015).
83. Ma, X., Chen, C. & Yang, J. Predictive model of blood-brain barrier penetration of organic compounds. *Acta Pharmacol Sin* **26**, 500–512 (2005).
84. Zhao, Y. H. *et al.* Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure–activity relationship (QSAR) with the Abraham descriptors. *J Pharm Sci* **90**, 749–784 (2001).
85. Yamashita, S. *et al.* Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. *European Journal of Pharmaceutical Sciences* **10**, 195–204 (2000).
86. Widiyana, A. P. *Jurnal Farmasi Sains dan Praktis Desain Komputasi dari Turunan Senyawa Kuinazolin-4(3H)-on sebagai Inhibitor Siklooksigenase-2 (COX-2)*. *JFSP* vol. 7 <http://journal.umngl.ac.id/index.php/pharmacy> (2021).